Бузерелин (Buserelin)

Buserelin is a synthetic analogue of GnRH, also known as follicle-stimulating hormone-releasing hormone (FSHR). It is used to treat endometriosis and prostate cancer.

Endometriosis is a condition in which tissue similar to the tissue that forms the lining of the uterus grows outside the uterus, causing painful and long menstrual cycles. Buserelin may help reduce the symptoms of endometriosis by reducing tissue growth and reducing pain.

Additionally, buserelin may be used as part of the treatment for prostate cancer in men. Prostate cancer is a tumor that forms in the prostate gland in men. Buserelin may help slow the growth of cancer cells that require male hormones to grow and develop.

Buserelin is usually prescribed as a nasal aerosol. This allows the medicine to quickly enter the bloodstream and begin to work. However, like any other medicine, buserelin can cause side effects.

Some of the possible side effects may include facial flushing and warmth, headache, emotional disturbances and decreased sex drive. However, not all patients taking buserelin experience these side effects, and they are usually temporary.

Buserelin is available under various trade names, including Suprecur and Suprefact. It should be used only as prescribed by a doctor and should not be used without consulting a medical professional.

Overall, buserelin is an effective medication for treating endometriosis and prostate cancer, although it may cause side effects. If you think buserelin may be the right treatment for you, discuss it with your doctor to determine which course of treatment is best for you.

Buserelin is a drug that is used to treat various diseases. One of the most common uses of buserelin is to treat endometriosis, a disease in which uterine tissue grows outside the uterus.

Buserelin is an analogue of the LH hormone, which plays an important role in the regulation of the menstrual cycle. When treating endometriosis, buserelin is administered as an aerosol directly into the nose. This allows the medicine to be delivered directly to the site of the disease, which helps reduce the symptoms of the disease and improve the general condition of the patient.

However, like any medicine, buserelin can cause side effects. Some of them include flushing, feeling hot, headache, emotional disturbances and decreased sex drive.

Trade names for buserelin include suprecur and suprefact. They are available in various forms, including aerosol, tablets and injections. It is important to note that buserelin should only be taken under the supervision of a doctor and as prescribed. Self-medication is unacceptable and can lead to serious consequences.

Busereline is a drug based on an analogue of gonadotropin-releasing hormone of synthetic origin. It is introduced into the body through the nasal cavity as a spray, which allows it to be used not only for the treatment of gynecological diseases. Side effects during the course of treatment are quite typical for all LH-RH analogues. However, in the case of buserelin, such symptoms appear more often or are more pronounced.

First of all, when the medicine is instilled into the nasal passages, a red face appears, and sometimes the patient feels a slight burning sensation and intense heat, resulting in a headache. The emotional sphere often suffers from decreased libido, accompanied by a lack of energy, headaches, and depression. Some women over 50 years of age, due to the occurrence of such symptoms, sometimes completely refuse treatment with this drug.

The hormone in question acts like leuprolide during menopause; approximately 3 days after using buserelin, the first positive signs begin to appear (blood flow to the follicles of the reproductive system) and weaken; after a month, some fading of these processes is noted. The process of exposure to the drug continues for several months or even years.

The effectiveness of buserelin is 30-50% in the treatment of prostate cancer (the affected disease takes a long time to make itself felt). Since this disease is associated with active hormone production. Its administration takes 2 weeks or a little more; immediately before the course, a series of studies are carried out to determine an accurate diagnosis. If treatment is successfully completed, several subsequent urine PSA tests should show a significant decrease. If the condition does not improve or progresses, this indicates the ineffectiveness of the therapy.